&l;p&g;&l;img class=&q;dam-image bloomberg size-large wp-image-41695972&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/41695972/960×0.jpg?fit=scale&q; data-height=&q;639&q; data-width=&q;960&q;&g; Jeff Sessions, U.S. attorney general, pauses after speaking during a House Judiciary Committee hearing in Washington, D.C., U.S., on Tuesday, Nov. 14, 2017. Andrew Harrer/Bloomberg
Marijuana stocks and exchange-traded funds were on fire in the New Year until Attorney General Jeff Sessions ignited a selloff Thursday upon announcing that he&a;rsquo;s retracting the Cole Memo, which lets individual states legalize cannabis without fear federal prosecutors will go after companies for trafficking.
Cannabics Pharmaceuticals, Medical Marijuana, United Cannabis, GreenGro Technologies, MassRoots and mCig crashed 25% to 30% each after flying high the two sessions prior as California&a;rsquo;s new marijuana laws went into effect. ETFMG Alternative Harvest ETF plunged 6%. Its Canadian counterpart, Horizons Marijuana Life Sciences Index ETF, dropped 8%. It trades over the counter in the U.S. under the ticker HMLSF.
Hot Canadian Stocks To Buy Right Now: Safeway Inc.(SWY)
- [By Peter Graham]
A long term performance chart shows shares of SUPERVALU underperforming the underperformance ofmid caps Whole Foods Market, Inc (NASDAQ: WFM) and Safeway Inc (NYSE: SWY). while large capKroger Co (NYSE: KR)had outperformed up until the last two years when performance has been more mixed:
- [By Peter Graham]
A long term performance chart shows shares of small cap SUPERVALU now underperforming large cap Kroger Co (NYSE: KR) while shares of large cap Whole Foods Market, Inc (NASDAQ: WFM) and mid cap Safeway Inc (NYSE: SWY) appear to be back to where they started at:
Hot Canadian Stocks To Buy Right Now: NRG Energy Inc.(NRG)
- [By Rich Duprey]
I ran a screen to identify the best-performing stocks from the S&P 500 in January. The top three performers during the month were Alcoa (NYSE:AA), CSX (NASDAQ:CSX), and NRG Energy (NYSE:NRG). Let’s see why they were the big standouts and whether they can keep it going.
- [By Ben Levisohn]
NRG Energy (NRG) soared to the top of the S&P 500 today.
NRG Energygained 4.5% to $12.85 today, while the S&P 500 advanced 0.2% to 2,262.53.
In a note released on Dec. 15, Morgan Stanley’sStephen Byrd and team summarized the reasoning behind their overweight rating on NRG:
NRG Energy (NRG, Overweight, $21 PT) FCF/Equity yield of ~35% and balanced upside from diversified market exposure, higher PJM capacity prices, fleet optimization, and debt reduction. NRG’s generation plus retail matching strategy is an underappreciated source of value, and provides stable cash flow despite current depressed power prices in Texas.
NRG Energy’s market capitalization rose to $4.1 billion today from $3.8 billion yesterday. It reported a net loss of $6.4 billion on sales of $15 billion in 2015.
NRG Energy was the Biggest Loser on Nov. 10, and the Hot Stock on Nov. 4.
- [By Lisa Levin]
In trading on Wednesday, utilities shares fell 0.25 percent. Meanwhile, top losers in the sector included NRG Energy Inc (NYSE: NRG), down 3 percent, and Entergy Corporation (NYSE: ETR) down 1 percent.
- [By Craig Jones]
Pete Najarian said that there was a big options activity in NRG Energy Inc (NYSE: NRG). Traders were aggressively buying the October 26 calls. Around 6,000 contracts were traded in the first half of the session and they were paying 65 cents for them. The trade breaks even at $26.65 or more than 11 percent above the current market price.
Hot Canadian Stocks To Buy Right Now: Valeant Pharmaceuticals International Inc(VRX)
- [By Lee Jackson]
These companies also reported insider buying last week: Apache Corp. (NYSE: APA), Halliburton Co. (NYSE: HAL), Revlon Inc. (NYSE: REV), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and U.S. Steel Corp. (NYSE: X).
- [By Keith Speights]
It’s been a long time since Valeant Pharmaceuticals (NYSE:VRX) stock was in a legitimate uptrend. Despite the hiring of a new CEO last year to right the ship, Valeant’s share price has continued to fall.
- [By Ben Levisohn]
The gain is particularly striking considering the fact that Endo International dropped 73% in 2016, making it the worst performer in the S&P 500. Endo has been hit hard by concerns over drug pricing that has plagued the entire specialty pharmaceutical sector since Valeant Pharmaceuticals International’s (VRX) pricing strategy came to light last year.
- [By Casey Wilson]
As disgraceful as Mylan’s pricing strategy may be, this next pharmaceutical firm is hated even more – and makes our list for the second year in a row…
Most-Hated Companies 2016 No. 1: Valeant Pharmaceuticals International Inc. (NYSE: VRX)
The troubled pharmaceutical company is deeply loathed by both consumers and investors alike.
- [By Kumar Abhishek]
Shares of specialty pharma company Valeant Pharmaceuticals Intl Inc(NYSE:VRX)have tanked more than 20% in last two trading sessions, breaching the support from the 50 day SMA, after the Laval,Quebec-based company reported its Q4 and FY 2016 earnings on Tuesday, before the market opened. While the earnings itself were better than expected, the guidance for FY 2017 didn’t go down well with investors and wall street, earning the company multiple price target cuts. Valeant reported an adjusted profit of $1.26 a share against analysts’ estimateof $1.21. This was Valeant’s first beat in a long time. Even on the revenue front, the company reported better than expected results. Initially, the stock gained on the report of an earnings beat. However, once the guidance figures came in, the stock tanked. In our earnings preview of Valeant, we had said that the adjusted EBITDA guidance for 2017 will be the key driver of VRX stock after the earnings.
- [By Paul Ausick]
Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 0.1% Thursday to post a new 52-week low of $9.49 after closing Wednesday at $9.50. The stock’s 52-week high is $38.50. Volume of about 15 million shares was about 25% below the daily average of around 19 million. The company had no specific news.
Hot Canadian Stocks To Buy Right Now: Patni Computer Systems Limited(PTI)
- [By Lisa Levin]
Proteostasis Therapeutics Inc (NASDAQ: PTI) shares shot up 162 percent to $6.16 after the company disclosed 'positive' PTI-428 data with statistical significance.
- [By William Romov]
Before we show you our pick, here are the top 10 penny stocks to watch this week
Penny Stock Current Share Price Nov. 27-Dec. 1 Gain (as of Dec. 1)
Pyxis Tankers Inc. (Nasdaq: PXS) $4.10 122.83%
Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.28 68.42%
Cerecor Inc. (Nasdaq: CERC) $1.74 47.46%
Proteostasis Therapeutics Inc. (Nasdaq: PTI) $2.52 37.71%
UT Starcom Holdings Corp. (Nasdaq: UTSI) $5.20 37.20%
WMIH Corp. (Nasdaq: WMIH) $0.96 33.46%
PhaseRx Inc. (Nasdaq: PZRX) $0.90 30.29%
Bellerophon Therapeutics Inc. (Nasdaq: BLPH) $2.04 29.94%
EV Energy Partners LP (Nasdaq: EVEP) $0.86 27.76%
Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX) $4.40 25.71%
FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, its completely free
Hot Canadian Stocks To Buy Right Now: Plains All American Pipeline L.P.(PAA)
- [By Dustin Parrett]
We think Plains All American Pipeline L.P. (NYSE: PAA) is one of the best oil stocks to buy this year. In fact, we see a scenario where PAA stock could jump 20% in 2017.
- [By Dustin Parrett]
Plains All American Pipeline (NYSE: PAA) controls 4 million barrels of crude oil and natural gas a day.
And with higher oil prices and fewer restrictions leading to more drilling, PAA’s pipelines will be in demand in 2017.
- [By Matthew DiLallo]
One of the largest projects is the Saddlehorn Pipeline, which Magellan is building with Plains All American Pipeline (NYSE:PAA) and Anadarko Petroleum (NYSE:APC). Both Plains All American Pipeline and Magellan own 40% of the project, which puts their total investment at $230 million apiece. They expect the project to be fully operational early next year, which is noteworthy given its robust first-year economics. Magellan estimates that it will earn eight times EBITDA on the capital deployed, or roughly $28.8 million in annual EBITDA apiece for Magellan and Plains All American Pipeline on their investment.
Hot Canadian Stocks To Buy Right Now: Nu Skin Enterprises Inc.(NUS)
- [By Roberto Pedone]
Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.
Monday’s Volume: 2 million
Three-Month Average Volume: 900,802
Volume % Change: 85%
From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.
Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.
- [By Ben Levisohn]
Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:
“Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…
Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.
Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.
Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.
- [By Craig Jones]
Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.